Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for
Nuclear medicine vendor SMV has revamped its executive lineup,a move that has resulted in the departure of Colin McNaught, chairmanand CEO of the vendor's SMV America unit in Twinsburg OH, andAndre Debionne, chairman and CEO of the holding company for SMVAmerica and SMV International.
SMV spokesperson Robert Ripley said that Debionne's positionwas a transitional one designed to help smooth the integrationof SMV's predecessors, Sopha and Summit Nuclear, while McNaughtdeparted for personal reasons. McNaught previously was head ofSopha's U.S. unit.
Neither McNaught nor Debionne will be replaced, according toRipley. SMV International chief executive Jean Plazenet will assumethe responsibilities of both executives. Summit veteran RandallSommerdyke remains president of SMV America, Ripley said.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.